4β-[(4-Alkyl)-1,2,3-triazol-1-yl] podophyllotoxins as anticancer compounds: Design, synthesis and biological evaluation

European Journal of Medicinal Chemistry

Volumn 46, Issue 6, 2011, Pages 1983-1991

  Reddy, Doma Mahendhar ^b   Srinivas, Jada ^a   Chashoo, Gousia ^b   Saxena, Ajit K ^b   Sampath Kumar, H M ^a,b  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Anticancer activity; Cell cycle analysis; Docking study; Podophyllotoxin; Topoisomerase II

Indexed keywords

4' O DEMETHYL 4BETA [(4 BUTYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4' O DEMETHYL 4BETA [(4 DECYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4' O DEMETHYL 4BETA [(4 ETHYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4' O DEMETHYL 4BETA [(4 HEPTYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4' O DEMETHYL 4BETA [(4 HEXYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4' O DEMETHYL 4BETA [(4 HYDROXYMETHYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4' O DEMETHYL 4BETA [(4 OCTYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4' O DEMETHYL 4BETA [(4 PENTYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4' O DEMETHYL 4BETA [(4 PROPYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4BETA [(4 ALKYL) 1,2,3 TRIAZOL 1 YL] PODOPHYLLOTOXIN DERIVATIVE; 4BETA [(4 BUTYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4BETA [(4 DECYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4BETA [(4 ETHYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4BETA [(4 HDYROXY METHYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4BETA [(4 HEPTYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4BETA [(4 HEXYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4BETA [(4 OCTYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4BETA [(4 PENTYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; 4BETA [(4 PROPYL) 1,2,3 TRIAZOL 1 YL] 4 DESOXYPODOPHYLLOTOXIN; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GYRASE INHIBITOR; PODOPHYLLOTOXIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN MCF 7; COLON CANCER; COMPUTER MODEL; DNA FRAGMENTATION; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FLOW CYTOMETRY; HEP 2 CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER CANCER; LUNG CANCER; MOLECULAR DOCKING; NEUROBLASTOMA; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PODOPHYLLOTOXIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79955589487     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.02.016     Document Type: Article

References (26)

1. M.G. Kelly, J.L. Hartwell, J. Natl. Cancer Inst. 14 (1954) 967-1010.
2. T. Imbert, Biochimie 80 (1998) 207-222.
3. L. Bohlin, B. Rosen, Drug Discov. Today 1 (1996) 343-351.
4. A. Jordan, J.A. Hadfield, N.J. Lawrence, A.T. McGown, Med. Res. Rev. 18 (1998) 259-296.
5. I. Jardine, in: J.M. Cassady, J. Douros (Eds.), Anticancer Agents Based on Natural Product Models, Academic Press, New York, 1980, pp. 319-351.
6. K.H. Lee, S.A. Beers, M. Mori, Z. Wang, Y. Kuo, L. Li, S. Liu, Y. Cheng, F. Han, Y. Cheng, J. Med. Chem. 33 (1990) 1364-1368.
7. H. Stahelin, A. Von Wartburg, Prog. Drug Res. 33 (1989) 169-267.
8. T.W. Doyle, Etoposide (VP-16) Current Status and New Developments. Academic, New York, 1984.
9. Z. Wang, Y. Kuo, J. Schnur, J. Bowen, S. Liu, F. Hen, J. Chang, Y. Cheng, K.H. Lee, J. Med. Chem. 33 (1990) 2660-2666.
10. B.F. Issell, Cancer Chemother. Pharmacol. 7 (1982) 73-80.
11. D.R. Budman, Semin. Oncol. 23 (1996) 8-14.
12. F.A. Greco, J.D. Hainsworth, Semin. Oncol. 23 (1996) 40-47.
13. T.L. Macdonald, E.K. Lehenert, J.T. Loper, K.C. Chow, W.E. Ross, DNA Topoisomerase in Cancer. Oxford University, New York, 1991, pp. 119.
14. D.L. Sackett, Pharmacol. Ther. 59 (1993) 163-228.
15. B.A. Bhat, P.B. Reddy, S.K. Agrawal, A.K. Saxena, H.M.S. Kumar, G.N. Qazi, Eur. J. Med. Chem. 43 (2008) 2067-2072.
16. P.B. Reddy, S.K. Agrawal, S. Singh, B.A. Bhat, A.K. Saxena, H.M.S. Kumar, G.N. Qazi, Chem. Biodivers. 5 (2008) 1792-1802.
17. P.B. Reddy, D.V. Paul, S.K. Agrawal, A.K. Saxena, H.M.S. Kumar, G.N. Qazi, Arch. Pharm. (Weinheim) 341 (2) (2008) 126-131.
18. H.C. Kolb, M.G. Finn, K.B. Sharpless, Angew. Chem. Int. Ed. 40 (2001) 2004-2021.
19. R. Huisgen, Proc. Chem. Soc. 6 (1961) 357-369.
20. N.O. Karpinich, M. Tafani, R.J. Rothman, M.A. Russo, J.L. Farer, J. Biol. Chem. 277 (2002) 16547-16552.
21. A. Kamal, B.A. Kumar, M. Arifuddin, Tetrahedron Lett. 44 (2003) 8457-8459.
22. A. Kamal, N. Laxman, G. Ramesh, Bioorg. Med. Chem. Lett. 10 (2000) 2059-2062.
23. A.K. Patel, S. Patel, P.K. Naik, Curr. Res. J. Biol. Sci. 2 (1) (2010) 13-23.
24. C. Frei, S.M. Gasser, A.V. Kajava, D. Leroy, Biochemistry 40 (2001) 1624-1634.
25. G.A. Kaminski, R.A. Friesner, J. Tirado-Rives, W.J. Jorgensen, J. Phys. Chem. B 105 (2001) 6474-6487.
26. W.L. Jorgensen, D.S. Maxwell, J. Tirado-Rives, J. Am. Chem. Soc. 118 (1996) 11225-11236.